# Halozyme Therapeutics

Type: Company (HALO)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/halozyme-therapeutics
Canonical HTML page: https://getbiobrief.com/entity/halozyme-therapeutics

## Recent coverage (2 stories)

### Halozyme's ENHANZE drives 47.7% revenue surge and FY26 EPS guidance 8% above Street
2026-08-12 02:48:54 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Halozyme's Q2 2026 earnings showcased accelerating adoption of its ENHANZE drug delivery technology, with royalties from subcutaneous biologics like DARZALEX FASPRO pushing revenue up 47.7% YoY. The company issued FY2026 EPS guidance of $8.65-$9.00, handily beating consensus, signaling sustained growth from its partnered pipeline.
Full story: https://getbiobrief.com/story/halozyme-enhanze-partner-royalties-q2-2026-guidance

### Halozyme Revenue Beats Estimates Amidst Massive $2.44 EPS Miss
2026-02-19 04:10:57 · Sentiment: Negative · Impact: 6/10 · Sources: 3

Halozyme Therapeutics reported a strong revenue beat of $451 million for the fourth quarter, driven by its ENHANZE platform royalties, yet surprised investors with a significant non-GAAP EPS miss of $2.44. The discrepancy suggests substantial one-time charges or strategic shifts that contrast with the company's robust top-line growth.
Full story: https://getbiobrief.com/story/halozyme-q4-2025-earnings-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.